Get started
Author

Mai Todoroki

Flutamide Promotes Early Hepatocarcinogenesis Through Mitophagy in High-Fat Diet-Fed Non-Obese Steatotic Rats
2025 · Emika Hara, Kanami Ohshima, et al. · International Journal of Molecular Sciences · 5
Macro- and microscopic anatomy of the digestive tract in the red-eared slider (Emydidae: Trachemys scripta elegans)
2024 · Nonoha Miyai, Takuma Kozono, et al. · PLoS ONE · 4
PDF
5-Fluorocytosine induces fetal skeletal malformations in rats by altering expression of Homeobox genes
2020 · Takayuki Kumamoto, Mika Senuma, et al. · Fundamental Toxicological Sciences · 4
PDF
Peroxisome Proliferator Activator α Agonist Clofibrate Induces Pexophagy in Coconut Oil-Based High-Fat Diet-Fed Rats
2024 · Kanami Ohshima, Emika Hara, et al. · Biology · 3
PDF
Induction of a thoracolumbar supernumerary rib in rat developmental toxicity studies: A short discussion on the critical window
2018 · Makiko Kuwagata, Mika Senuma, et al. · Congenital Anomalies · 3
Wnt and Treg-Associated Signaling Coordinate Mucosal Regeneration and MALT Formation in a Mouse Model of Chronic Colitis
2026 · Nanami Watanabe, Mio Kobayashi, et al. · International Journal of Molecular Sciences · 1
PDF
Autophagy suppression is associated with enhanced preneoplastic hepatocellular lesions in rats fed a lard-containing high-fat diet
2026 · Ayumi Karasawa, Mio Takimoto, et al. · Food and Chemical Toxicology
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S6 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S5 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Data from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 1 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Table S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 4 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Table 2 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Supplementary Figure S7 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Figure 3 from ZSTK3744, a Novel Aryl Hydrocarbon Receptor Agonist, Exhibits Efficacy against Chemotherapy-Resistant Triple-Negative Breast Cancer
2026 · Takahiro Ohashi, Tsubasa Nagasaki, et al.
Works count: 38
Citation count: 20
H-index: 3
I10-index:
Year
Topic
Type